BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed DCTH catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:189f4fe0b3097c17cd7b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DCTH P2 readout (est.): DEL-LIVER
DESCRIPTION:Evaluation of the Safety and Efficacy of Treatment w/High Dose 
 Melphalan Given Directly Into the Liver Followed by Treatment w/Approved C
 ancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastat
 ic Colorectal Cancer w/Liver Dominant Disease\nNCT06607458 | PHASE2 | RECR
 UITING | sponsor: Delcath Systems Inc.\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nTicker DCTH (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT06607458\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06607458
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
